Report copyright - Rociletinib (CO-1686) · 2015. 4. 14. · Rociletinib (CO-1686) causes tumor regression in front-line L858R transgenic model • No cell line based models with EGFR L858R mutation
Please pass captcha verification before submit form
Please pass captcha verification before submit form